Print Email Facebook Twitter ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study Title ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study Author Ceconi, C. Fox, K.M. Remme, W.J. Simoons, M.L. Deckers, J.W. Bertrand, M. Parrinello, G. Kluft, C. Blann, A. Cokkinos, D. Ferrari, R. TNO Kwaliteit van Leven Publication year 2009 Abstract The PERTINENT study measured biomarkers of atherosclerosis and thrombosis in a stable coronary artery disease population from EUROPA receiving ACE inhibition with perindopril 8 mg/day or placebo. Biomarkers of inflammation, C-reactive protein (CRP), fibrinogen, and tumor necrosis factor-alpha (TNF-α), and a biomarker of thrombosis, d-dimer, were measured at baseline and 1 year. CRP was recorded in 1157 patients; fibrinogen, TNF-α, and d-dimer in 291 patients. There was no significant effect of treatment on CRP or fibrinogen. In contrast, there were significant reductions in TNF-α (27.60-25.20 pg/mL; P < 0.05) and d-dimer (0.24-0.18 μg/mL; P < 0.05) with perindopril over 1 year. Survival analysis of the prognostic significance of baseline CRP failed to detect a significant role for the prediction of cardiovascular events over 4 years (lower versus higher tertile: 1.54; 95% confidence interval 0.88-2.68; P = 0.16). In conclusion, in the PERTINENT trial, we observed significant effects of ACE inhibition on biomarkers of the atherothrombotic complications (d-dimer) and the proinflammatory cytokine TNF-α, but not on biomarkers of inflammation associated with atherosclerosis (CRP and fibrinogen). © 2008. Subject HealthBiomedical ResearchACE inhibitionCoronary artery diseaseInflammationPerindoprilThrombosisbiological markerC reactive proteinD dimerdipeptidyl carboxypeptidase inhibitorfibrinogenperindoprilplacebotumor necrosis factor alphaarticleatherosclerosisclinical trialcontrolled clinical trialcontrolled studycoronary artery diseasedrug effectdrug efficacydrug responseendothelial dysfunctionhumaninflammationmajor clinical studypredictionpriority journalprognosissurvivalthrombosistreatment durationtreatment outcometreatment responseAngiotensin-Converting Enzyme InhibitorsBiological MarkersC-Reactive ProteinCardiovascular DiseasesCoronary Artery DiseaseCoronary ThrombosisDouble-Blind MethodEuropeFibrin Fibrinogen Degradation ProductsFibrinogenHumansInflammationInflammation MediatorsKaplan-Meiers EstimatePerindoprilProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeTumor Necrosis Factor-alpha To reference this document use: http://resolver.tudelft.nl/uuid:9afbc9f9-330d-4448-a48b-ce196d43029d DOI https://doi.org/10.1016/j.atherosclerosis.2008.08.042 TNO identifier 241499 ISSN 0021-9150 Source Atherosclerosis, 204 (1), 273-275 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.